image
Healthcare - Medical - Instruments & Supplies - NYSE - CA
$ 12.49
-0.0829 %
$ 4.41 B
Market Cap
-13.39
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one BLCO stock under the worst case scenario is HIDDEN Compared to the current market price of 12.5 USD, Bausch + Lomb Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one BLCO stock under the base case scenario is HIDDEN Compared to the current market price of 12.5 USD, Bausch + Lomb Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one BLCO stock under the best case scenario is HIDDEN Compared to the current market price of 12.5 USD, Bausch + Lomb Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BLCO

image
$21.0$21.0$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
4.77 B REVENUE
15.15%
162 M OPERATING INCOME
24.62%
-305 M NET INCOME
-22.98%
232 M OPERATING CASH FLOW
1464.71%
-412 M INVESTING CASH FLOW
80.46%
178 M FINANCING CASH FLOW
-91.43%
1.28 B REVENUE
7.02%
87 M OPERATING INCOME
102.33%
-2 M NET INCOME
-13.33%
22 M OPERATING CASH FLOW
-85.71%
-185 M INVESTING CASH FLOW
-92.71%
146 M FINANCING CASH FLOW
830.00%
Balance Sheet Bausch + Lomb Corporation
image
Current Assets 2.79 B
Cash & Short-Term Investments 305 M
Receivables 1.03 B
Other Current Assets 1.46 B
Non-Current Assets 10.7 B
Long-Term Investments 0
PP&E 1.48 B
Other Non-Current Assets 9.2 B
7.62 %10.82 %11.03 %68.28 %Total Assets$13.5b
Current Liabilities 1.74 B
Accounts Payable 389 M
Short-Term Debt 40 M
Other Current Liabilities 1.31 B
Non-Current Liabilities 5.19 B
Long-Term Debt 4.74 B
Other Non-Current Liabilities 443 M
5.62 %18.90 %68.51 %6.40 %Total Liabilities$6.9b
EFFICIENCY
Earnings Waterfall Bausch + Lomb Corporation
image
Revenue 4.77 B
Cost Of Revenue 1.87 B
Gross Profit 2.9 B
Operating Expenses 2.76 B
Operating Income 162 M
Other Expenses 467 M
Net Income -305 M
5b5b4b4b3b3b2b2b1b1b00(1b)(1b)5b(2b)3b(3b)162m(467m)(305m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
60.79% GROSS MARGIN
60.79%
3.39% OPERATING MARGIN
3.39%
-6.64% NET MARGIN
-6.64%
-4.90% ROE
-4.90%
-2.35% ROA
-2.35%
1.79% ROIC
1.79%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Bausch + Lomb Corporation
image
700m700m600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)20192019202020202021202120222022202320232024202420252025
Net Income -305 M
Depreciation & Amortization 436 M
Capital Expenditures -291 M
Stock-Based Compensation 92 M
Change in Working Capital 0
Others 19 M
Free Cash Flow -59 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Bausch + Lomb Corporation
image
Wall Street analysts predict an average 1-year price target for BLCO of $21.3 , with forecasts ranging from a low of $18 to a high of $25 .
BLCO Lowest Price Target Wall Street Target
18 USD 44.12%
BLCO Average Price Target Wall Street Target
21.3 USD 70.54%
BLCO Highest Price Target Wall Street Target
25 USD 100.16%
Price
Max Price Target
Min Price Target
Average Price Target
262624242222202018181616141412121010Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Bausch + Lomb Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
505 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Bausch + Lomb (BLCO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / April 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bausch + Lomb ("Bausch & Lomb" or "the Company") (NYSE:BLCO). Investors who purchased Bausch & Lomb securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BLCO. accessnewswire.com - 3 weeks ago
Bausch + Lomb (BLCO) Moves 13.9% Higher: Will This Strength Last? Bausch + Lomb (BLCO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com - 3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages Bausch + Lomb (BLCO) Shareholders to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / April 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bausch + Lomb ("Bausch & Lomb" or "the Company") (NYSE:BLCO). Investors who purchased Bausch & Lomb securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BLCO. accessnewswire.com - 3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Bausch + Lomb (BLCO) And Encourages Shareholders to Connect NEW YORK CITY, NY / ACCESS Newswire / April 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bausch + Lomb ("Bausch & Lomb" or "the Company") (NYSE:BLCO). Investors who purchased Bausch & Lomb securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BLCO. accessnewswire.com - 3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bausch + Lomb (BLCO) And Encourages Shareholders to Reach Out NEW YORK CITY, NY / ACCESS Newswire / April 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bausch + Lomb ("Bausch & Lomb" or "the Company") (NYSE:BLCO). Investors who purchased Bausch & Lomb securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BLCO. accessnewswire.com - 3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bausch + Lomb (BLCO) and Encourages Investors to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bausch + Lomb ("Bausch & Lomb" or "the Company") (NYSE:BLCO). Investors who purchased Bausch & Lomb securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BLCO. accessnewswire.com - 3 weeks ago
Bausch + Lomb (BLCO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bausch + Lomb ("Bausch & Lomb" or "the Company") (NYSE:BLCO). Investors who purchased Bausch & Lomb securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BLCO. accessnewswire.com - 3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Bausch + Lomb (BLCO) And Encourages Investors to Connect NEW YORK CITY, NY / ACCESS Newswire / April 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bausch + Lomb ("Bausch & Lomb" or "the Company") (NYSE:BLCO). Investors who purchased Bausch & Lomb securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BLCO. accessnewswire.com - 4 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages Bausch + Lomb (BLCO) Stockholders to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bausch + Lomb ("Bausch & Lomb" or "the Company") (NYSE:BLCO). Investors who purchased Bausch & Lomb securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BLCO. accessnewswire.com - 4 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bausch + Lomb (BLCO) and Encourages Stockholders to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bausch + Lomb ("Bausch & Lomb" or "the Company") (NYSE:BLCO). Investors who purchased Bausch & Lomb securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BLCO. accessnewswire.com - 1 month ago
BLCO ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Bausch Lomb Corporation Shareholders Who Lost Money NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Bausch Lomb Corporation ("Bausch Lomb Corporation") (NYSE:BLCO) concerning possible violations of federal securities laws. Bausch & Lomb announced a voluntary recall of intraocular lenses on its enVista platform on March 27, 2025, due to reports of toxic anterior segment syndrome (TASS), a potential complication in cataract surgery. accessnewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Encourages Bausch + Lomb (BLCO) Investors to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / March 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bausch + Lomb ("Bausch & Lomb" or "the Company") (NYSE:BLCO). Investors who purchased Bausch & Lomb securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BLCO. accessnewswire.com - 1 month ago
8. Profile Summary

Bausch + Lomb Corporation BLCO

image
COUNTRY CA
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 4.41 B
Dividend Yield 0.00%
Description Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Contact 520 Applewood Crescent, Vaughan, ON, L4K 4B4 https://www.bausch.com
IPO Date May 6, 2022
Employees 13500
Officers Dr. Yehia Hashad M.D., Ph.D. Executive Vice President of Research & Development and Chief Medical officer Mr. Andrew J. Stewart President of Global Pharmaceuticals & International Consumer Mr. Brenton L. Saunders J.D. Chief Executive Officer & Chairman Mr. Frederick J. Munsch Senior Vice President, Controller & Chief Accounting Officer Mr. A. Robert D. Bailey Executive Vice President & Chief Legal Officer Mr. Alan Waterhouse CPFA, MBA Executive Vice President and Chief Supply Chain & Operations Officer Mr. T.J. Crawford Chief Communications Officer Dr. Manisha A. Narasimhan Ph.D. Chief Corporate Development & Digital Officer Mr. Jonathon L. Kellerman Chief Compliance Officer Mr. Osama A. Eldessouky Executive Vice President & Chief Financial Officer